These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 20673702)
1. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease. Surendran S Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702 [TBL] [Abstract][Full Text] [Related]
2. Upregulation of N-acetylaspartic acid induces oxidative stress to contribute in disease pathophysiology. Surendran S; Bhatnagar M Int J Neurosci; 2011 Jun; 121(6):305-9. PubMed ID: 21348802 [TBL] [Abstract][Full Text] [Related]
3. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013 [TBL] [Abstract][Full Text] [Related]
4. Novel splice site mutation of aspartoacylase gene in a Turkish patient with Canavan disease. Rady PL; Penzien JM; Vargas T; Tyring SK; Matalon R Eur J Paediatr Neurol; 2000; 4(1):27-30. PubMed ID: 10701101 [TBL] [Abstract][Full Text] [Related]
5. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674 [TBL] [Abstract][Full Text] [Related]
6. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262 [TBL] [Abstract][Full Text] [Related]
7. Atypical MRI findings in Canavan disease: a patient with a mild course. Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711 [TBL] [Abstract][Full Text] [Related]
8. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease. Eke GH; Iscan A; Cece H; Calik M Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636 [TBL] [Abstract][Full Text] [Related]
9. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Kaul R; Balamurugan K; Gao GP; Matalon R Genomics; 1994 May; 21(2):364-70. PubMed ID: 8088831 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical localization of aspartoacylase in the rat central nervous system. Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127 [TBL] [Abstract][Full Text] [Related]
12. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
13. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192 [TBL] [Abstract][Full Text] [Related]
14. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion. Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223 [TBL] [Abstract][Full Text] [Related]
15. Upregulation of aspartoacylase activity in the duodenum of obesity induced diabetes mouse: implications on diabetic neuropathy. Surendran S; Matalon R; Tyring SK Biochem Biophys Res Commun; 2006 Jul; 345(3):973-5. PubMed ID: 16707098 [TBL] [Abstract][Full Text] [Related]
16. Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene. Janson CG; Kolodny EH; Zeng BJ; Raghavan S; Pastores G; Torres P; Assadi M; McPhee S; Goldfarb O; Saslow B; Freese A; Wang DJ; Bilaniuk L; Shera D; Leone P Ann Neurol; 2006 Feb; 59(2):428-31. PubMed ID: 16437572 [TBL] [Abstract][Full Text] [Related]
17. Canavan disease: clinical features and recent advances in research. Hoshino H; Kubota M Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939 [TBL] [Abstract][Full Text] [Related]
18. Aspartoacylase gene knockout in the mouse: impact on reproduction. Surendran S; Szucs S; Tyring SK; Matalon R Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664 [TBL] [Abstract][Full Text] [Related]
19. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881 [TBL] [Abstract][Full Text] [Related]
20. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Matalon R; Michals K; Sebesta D; Deanching M; Gashkoff P; Casanova J Am J Med Genet; 1988 Feb; 29(2):463-71. PubMed ID: 3354621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]